Combination Effect of Cilengitide with Erlotinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition in Human Non-Small Cell Lung Cancer Cells

Jisu Jeong and Jiyeon Kim *

Department of Medical Laboratory Science, School of Health Science, Dankook University, Cheonan 31116, Korea; jjs0892@hanmail.net

* Correspondence: yeon@dankook.ac.kr

Abstract: The epithelial-to-mesenchymal transition (EMT) is important for morphogenesis during development and is mainly induced by transforming growth factor (TGF)-β. In lung cancer, EMT is characterized by the transformation of cancer cells into a mobile, invasive form that can transit to other organs. Here, using a non–small cell lung cancer (NSCLC) cell line, we evaluated the EMT-related effects of the epidermal growth factor receptor inhibitor erlotinib alone and in combination with cilengitide, a cyclic RGD-based integrin antagonist. Erlotinib showed anti-proliferative and inhibitory effects against the TGF-β1–induced EMT phenotype in NSCLC cells. Compared with erlotinib alone, combination treatment with cilengitide led to an enhanced inhibitory effect on TGF-β1–induced expression of mesenchymal markers and invasion in non–small cell lung cancer A549 cells. These results suggest that cilengitide could improve anticancer drug efficacy and contribute to improved treatment strategies to inhibit and prevent EMT-based cancer progression.

Keywords: NSCLC; A549; erlotinib; cilengitide; TGF-β1; EMT

1. Introduction

Among cancer deaths, lung cancer accounts for the largest share, with an incidence rate that is increasing every year worldwide [1]. Lung cancer occurs as one of two broad types, small cell lung cancer and non–small cell lung cancer (NSCLC). Of these, NSCLC accounts for approximately 80–85% of cases [1]. The NSCLC also has been classified into three main types: adenocarcinoma, squamous cell carcinoma, and large cell [2]. Depending on the epithelial nature of lung cancer, adenocarcinomas (approximately 70–75% of NSCLC) exhibit a completely different epithelial phenotype (derived from simple epithelium), whereas squamous cell carcinomas or epidermoid carcinomas of lung (25–30%) cancer are derived from keratinocytes or squamous (multilayered) epithelia of the lung. In these two tumor subtypes, cellular plasticity-related processes such as EMT and invasiveness have different properties and require different molecular mechanisms [2]. The process of cell conversion from epithelial to mesenchymal, known as the epithelial-to-mesenchymal transition (EMT), is normal in embryonic development, wound healing, and fibrosis [1,3]. In NSCLC, however, this transition represents a cellular shift from polarized, tightly bound epithelial cells to the motile and invasive fusiform mesenchymal cells of metastasis. For this reason, a candidate strategy for preventing NSCLC metastasis and invasion to other organs is inhibiting pathways associated with EMT, in addition to the use of conventional therapeutic drugs.

Among the factors that trigger the EMT process, one of the most important is a cytokine, transforming growth factor (TGF)-β [4–7]. In TGF-β–induced EMT, TGF-β binds to the transmembrane Ser/Thr receptors TGF-β type I (TβR-I) and type II (TβR-II), triggering phosphorylation of TβR-I, followed by downstream phosphorylation of the effectors Smad2 and Smad3 [8,9]. The phosphorylated Smad2/3 recruits Smad4 to form a
complex, then translocates from the cytoplasm to the nucleus and binds to transcription factors such as Snail/Slug and Twist to activate EMT-related genes [10–12]. The EMT process also can occur through non-Smad signaling pathways such as Wnt/β-catenin or MAPK/ERK [13–15].

Erlotinib (trade name Tarceva) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in NSCLC cells and, along with gefitinib, is a first-generation TKI used to treat NSCLC with EGFR mutation [16]. Erlotinib is approved by the U.S. Food and Drug Administration as a second-line treatment for NSCLC that has not responded to first-line treatment. Because long-term use can lead to resistance and side effects, it is combined with other therapies [17,18]. Various treatment strategies for overcoming the side effects of chemotherapy for NSCLC are being studied [19–25].

Cilengitide is a cyclic peptide based on a tripeptide RGD (arginine, glycine, aspartic acid)-containing structure and is used to increase therapeutic efficacy along with various drugs for the treatment of several tumors [26]. Since integrins involved in angiogenesis and metastasis in the tumor microenvironment can be recognized by substances containing RGD sequences, RGD-containing peptides or peptidomimetics targeting integrins can be utilized as candidates for anticancer chemotherapy [27–29]. Several in vitro or clinical studies have demonstrated the efficacy of cilengitide and the effect of co-administration with existing anticancer drugs, but few studies have been conducted on the mechanism for EMT inhibition in NSCLC and its combination with cancer therapeutics [30–35]. In addition, we recently described an enhancing effect of cilengitide with gefitinib on limiting TGF-β-mediated EMT in NSCLC cells. By inhibiting Smad and non-Smad signaling, cilengitide enhanced the effect of gefitinib on NSCLC cell death and TGF-β–induced EMT phenotype change without severe cytotoxicity in normal cells [36].

Here, we investigated the anticancer effect of erlotinib and its inhibition of TGF-β–induced EMT. We also assessed whether the combination of erlotinib and cilengitide could enhance the inhibitory effects of erlotinib on TGF-β–induced EMT while minimizing side effects.

2. Results

2.1. Erlotinib Inhibits TGF-B1–Induced EMT-Related Phenotype Changes

Before evaluating the effect of erlotinib on the TGF-β1–induced EMT process, we investigated cell viability in NSCLC A549, H1299, normal lung epithelium CPAE, and normal lung fibroblast IMR90 cells. Treatment with an erlotinib concentration of 1 µm or higher reduced the viability of A549 and H1299 cells (Figure 1A,B) but scarcely reduced the viability of CPAE cells (Figure 1C). In addition, the viability of IMR90 was slightly decreased compared with A549 and H1299.

TGF-β1 reduces expression of the epithelial marker E-cadherin but induces an increase in the mesenchymal markers N-cadherin, vimentin, and α-SMA [37,38]. For this reason, we checked the effect of erlotinib on the TGF-β1–induced EMT-related phenotype changes in NSCLC A549 and H1299 cells. As shown in Figure 2A and Figure S4, erlotinib suppressed expression of TGF-β1–related increases in N-cadherin, vimentin, and α-SMA in A549 and H1299 cells. However, the EMT-related decreased expression of E-cadherin did not fully recover with erlotinib. Moreover, in CPAE cells, erlotinib did not suppress the expression of EMT-related genes according to the concentration gradient (Figure S5).
Figure 1. Erlotinib inhibits proliferation of human NSCLC A549 and H1299 cells. (A) A549, (B) H1299, (C) CPAE, and (D) IMR90 cells were treated with erlotinib for 24–72 h. After incubation, cell viability was measured by the EZ-Cytox Enhanced Cell Viability Assay Kit. Experiments were performed in triplicate. Data represent mean ± SD.

The inhibitory effects of erlotinib were confirmed using the TGF-β1–mediated transcription of epithelial and mesenchymal marker genes CDH1, CDH2, and VIM (encoding E-cadherin, N-cadherin, and vimentin, respectively). Treatment with TGF-β1 decreased expression of CDH1 mRNA (Figure 2B) and increased expression of CDH2 (Figure 2C) and VIM mRNA (Figure 2D). However, the expression of CDH1 mRNA slightly recovered at 1 μM, and the expression of CDH2 and VIM mRNA was inhibited at erlotinib concentrations >1 μM. These results indicate that erlotinib concentrations >1 μM have inhibitory effects on TGF-β1–induced EMT-related phenotypic changes and related gene expression in A549 cells.
Figure 2. Erlotinib inhibits TGF-β1–induced expression of EMT markers. (A) Serum-deprived A549 cells were treated with TGF-β1 (5 ng/mL) or in combination with erlotinib for 72 h. Protein expression of an epithelial marker (E-cadherin) and mesenchymal markers (N-cadherin, vimentin, and α-smooth muscle actin) was determined by Western blot analysis. Actin was used as a loading control. (B–D) Serum-deprived A549 cells were incubated with TGF-β1 (5 ng/mL) and erlotinib for 48 h. After RNA extraction and cDNA synthesis, we performed qRT-PCR to measure the expression of CDH1, CDH2, and VIM mRNA using GAPDH as an internal control. # p < 0.01 versus control; * p < 0.05 versus the group treated with TGF-β1 only.

2.2. Erlotinib Inhibits Tgf-B1–Induced Smad and Non-Smad Signaling

Because the TGF-β1–induced EMT process could be modulated through the activation of Smad or non-Smad signaling [8,9,13–15], we investigated the effect of erlotinib on TGF-β1–induced Smad and non-Smad signaling pathways in A549 and H1299 cells. As shown in Figure 3A, erlotinib suppressed phosphorylation of Smad2/3. To determine whether erlotinib inhibits non-Smad signaling, we measured EGFR-triggered phosphorylation of downstream MAPK ERK1/2 and translocation of β-catenin into the nucleus. As shown in Figure 3B, Figures S6 and S7, erlotinib inhibited TGF-β1–induced phosphorylation of ERK1/2 and nuclear localization of β-catenin. In particular, erlotinib inhibited phosphorylation of the downstream target ERK1/2 more strongly than it inhibited Smad2/3 phosphorylation. These results suggest that erlotinib has an inhibitory effect on both Smad and non-Smad signaling mediating EMT progression in NSCLC cells.
whether erlotinib inhibits non-Smad signaling, we measured EGFR-triggered phosphor-
ylation of downstream MAPK ERK1/2 and translocation of β-catenin into the nucleus. As shown in Figures 3B, S6 and S7, erlotinib inhibited TGF-
β1–induced phosphorylation of ERK1/2 and nuclear localization of β-catenin. In particular, erlotinib inhibited phosphorylation of the downstream target ERK1/2 more strongly than it inhibited Smad2/3 phos-
phorylation. These results suggest that erlotinib has an inhibitory effect on both Smad and non-Smad signaling mediating EMT progression in NSCLC cells.

Figure 3. Erlotinib inhibits TGF-β1–induced Smad and non-Smad signaling pathways. Serum-deprived A549 cells were treated with TGF-β1 (5 ng/mL) with erlotinib for 48 h (A) or 72 h (B,C). Protein expression of the p-Smad2/3 (A), p-ERK1/2 (B), β-catenin (C), and endogenous forms of Smad2/3 and ERK1/2 was determined by Western blot analysis. Actin was used as a loading control.

2.3. Combination Cilengitide with Erlotinib Exerts a Synergistic Inhibitory Effect on NSCLC Cell Viability and EMT Markers

In a previous report on cilengitide combined with the EGFR inhibitor gefitinib, we confirmed their cytotoxicity in CPAE cells and a synergistic effect on NSCLC cell viability and TGF-β1–induced EMT phenotype changes [36]. Based on that study, we investigated the combined treatment effect of cilengitide with erlotinib on NSCLC cell viability and TGF-β1–induced EMT marker expression. As shown in Figure 4, compared to treatment with erlotinib or cilengitide (Figure 4A) alone, combined treatment exhibited a synergistic effect on A549 (Figure 4B) and H1299 cell proliferation (Figure 4C). The CI calculated using the raw data confirmed this result (Table 1 and Table S2, Figure S8). Synergistic effects were observed at concentrations >0.1 µM.

Table 1. Combination index (CI) values for the two-drug combination against A549 and H1299 cell viability.

| Cell line. | Erlotinib (µM) | Cilengitide (µM) | CI Value |
|------------|----------------|-----------------|----------|
| A549       | 0.1            | 0.1             | 0.2655   |
|            | 0.3            | 0.3             | 0.5058   |
|            | 1              | 1               | 0.6415   |
|            | 3              | 3               | 0.2346   |
|            | 10             | 10              | 0.0298   |
|            | 30             | 30              | 0.0100   |
| H1299      | 0.1            | 0.1             | 0.5450   |
|            | 0.3            | 0.3             | 0.7446   |
|            | 1              | 1               | 1.7137   |
|            | 3              | 3               | 0.4097   |
|            | 10             | 10              | 0.0357   |
|            | 30             | 30              | 0.0359   |
Figure 4. Cilengitide enhances the inhibitory effect of erlotinib on the cell viability of A549 and H1299 cells. (A) Chemical structure of cilengitide. (B) A549 and (C) H1299 cells were treated with erlotinib alone or with cilengitide for 24–72 h. After incubation, cell viability was measured by the CCK-8 assay. Experiments were performed in triplicate. Data represent mean ± SD.

We also evaluated the combination effect of cilengitide with erlotinib on protein and mRNA expression of EMT markers in A549 cells. As shown in Figure 5A, although combination treatment did not lead to recovery of the TGF-β1–induced decrease in E-cadherin, inhibition of N-cadherin, vimentin, and α-SMA was stronger with combined treatment than with erlotinib alone. To confirm the synergistic effect of the two combined drugs, we investigated their influence on Smad and non-Smad signaling. As shown in Figure 5B, the combination showed stronger inhibition than either agent singly against TGF-β1–induced phosphorylation of Smad2/3. In addition, TGF-β1–induced expression of β-catenin was suppressed more with combined treatment (Figure 5C), although the combination did not affect phosphorylation of EGFR or ERK1/2 more than either agent alone (Figure S9). These results indicate that combined treatment may enhance the efficacy of erlotinib in inducing NSCLC cell death and inhibit the TGF-β1–induced EMT process through the suppression of Smad and non-Smad Wnt/β-catenin signaling.
Figure 5B, the combination showed stronger inhibition than either agent singly against TGF-β1–induced phosphorylation of Smad2/3. In addition, TGF-β1–induced expression of β-catenin was suppressed more with combined treatment (Figure 5C), although the combination did not affect phosphorylation of EGFR or ERK1/2 more than either agent alone (Figure S9). These results indicate that combined treatment may enhance the efficacy of erlotinib in inducing NSCLC cell death and inhibit the TGF-β1–induced EMT process through the suppression of Smad and non-Smad Wnt/β-catenin signaling.

Figure 5. Effect of combined treatment on TGF-β1–induced EMT marker expression and Smad and non-Smad signaling. A549 cells were treated with gefitinib (1 μM) and cilengitide (3 μM) individually or in combination, and then incubated with TGF-β1 (5 ng/mL) for 72 h (A,C) or 48 h (B). (A) The expression of EMT markers was measured by Western blot analysis. Actin was used as a loading control. (B,C) The expression of protein was measured by Western blot analysis. β-actin was used as a loading control.

2.4. The Combination of Cilengitide with Erlotinib Exerts a Synergistic Inhibitory Effect on Tgf-B1–Mediated Invasion and MMP Secretion

We also tested the effect of cilengitide with erlotinib on TGF-β1–induced invasion in A549 cells. In our previous report, we confirmed that cilengitide has an inhibitory effect and that combined treatment with gefitinib yielded a synergistic effect [36]. As shown in Figure 6A, either erlotinib or cilengitide inhibited the TGF-β1–induced invasion of A549 cells across the gelatin-coated membrane, and their combination increased this inhibitory effect.

During extracellular matrix (ECM) disruption, matrix metalloproteinases (MMPs) cleave the ECM in ways that promote shape changes in cancer cells so that they can maintain viability and develop invasive and migratory properties [37]. We used gelatin zymography to investigate the combination effect of the major gelatinases MMP-2 and MMP-9 on TGF-β1–induced EMT activation. As shown in Figures S10 and S11, erlotinib treatment inhibited TGF-β1–induced gelatinase activities of both MMP-2 and MMP-9, but cilengitide did not significantly affect them. However, the combination of erlotinib and cilengitide yielded stronger inhibition than either agent singly (Figure 6B). Collectively, these results indicate that combined treatment with erlotinib and cilengitide can exert enhanced inhibitory effects on the TGF-β1–induced invasion process (Figure 7).
Figure 6. The combination of erlotinib and cilengitide exerts an enhanced inhibitory effect on TGF-β1–induced invasion and MMP activities in A549 cells. Serum-deprived A549 cells were treated with TGF-β1 (5 ng/mL) and erlotinib alone or in combination with cilengitide for 48 h. (A) The effect of the combination on TGF-β1–induced invasion of A549 cells was evaluated using Boyden chambers. Numbers of invaded cells were represented by an average number of cells per randomly selected three high-power field (HPF). (B) Activation of MMP-2 and MMP-9 was measured by gelatin zymography. # p < 0.01 versus control; * p < 0.05 versus the group treated with TGF-β1 only.

During extracellular matrix (ECM) disruption, matrix metalloproteinases (MMPs) cleave the ECM in ways that promote shape changes in cancer cells so that they can maintain viability and develop invasive and migratory properties [37]. We used gelatin zymography to investigate the combination effect of the major gelatinases MMP-2 and MMP-9 on TGF-β1–induced EMT activation. As shown in Figures S10 and S11, erlotinib treatment inhibited TGF-β1–induced gelatinase activities of both MMP-2 and MMP-9, but cilengitide did not significantly affect them. However, the combination of erlotinib and cilengitide yielded stronger inhibition than either agent singly (Figure 6B). Collectively,
these results indicate that combined treatment with erlotinib and cilengitide can exert enhanced inhibitory effects on the TGF-β1–induced invasion process (Figure 7).

Figure 7. Schematic of TGF-β-mediated EMT signaling pathways inhibited by combined treatment of erlotinib and cilengitide.

3. Discussion

Here we show that co-administration of cilengitide with erlotinib increases the inhibitory effects of erlotinib alone on NSCLC cell survival and TGF-β1–induced EMT changes. Collectively, these results suggest that EGFR inhibitors such as gefitinib and erlotinib, when combined with cilengitide, may synergize in the treatment of EMT-related diseases, including human lung cancer, pulmonary fibrosis, and other metastatic cancers.

During the progression of lung cancer, cells acquire metastatic and invasive properties through the EMT process [3,38]. This process also is responsible for maintaining NSCLC cell survival by activating anti-apoptotic signals that both alter cell shape to a mesenchymal phenotype and confer resistance to chemotherapy [39]. Therefore, in the treatment of NSCLC, inhibition of EMT along with the induction of cancer cell death can be an important therapeutic strategy for suppressing cancer cell metastasis. We confirmed this hypothesis in the current study, showing that the cyclic pentapeptide cilengitide is effective as co-treatment with erlotinib, an EGFR-targeting drug that induces NSCLC cell death, to increase inhibitory efficacy against TGF-β1–induced EMT and reduce metastatic potential in NSCLC.

For the treatment of NSCLC, drugs such as the TKIs erlotinib and gefitinib are used in chemotherapy, but long-term administration may cause side effects, including cancer cell resistance and the death of healthy cells [39]. To reduce these side effects and increase therapeutic efficacy, studies have increasingly focused on combined treatment therapies such as immunotherapy, radiation therapy, and targeted therapy [22]. In general, with combination drug therapy for NSCLC treatment, side effects arising from the use of small
molecule drugs can be reduced. In particular, cyclic peptides are being actively studied as biochemical tools and therapeutic agents because of their excellent in vivo stability and high affinity and selectivity for target molecule binding compared to linear peptides [40].

Cyclic peptides such as cRGDfK and cRGDyK exhibit high binding affinity and selectivity for the overexpressed integrins $\alpha_\nu \beta_3$ and $\alpha_\nu \beta_5$ in cancer cells, facilitating the delivery of anticancer drugs to the target [41,42]. We recently demonstrated that cRGDfK increased NSCLC apoptosis and enhanced the inhibitory effects of the TKI sunitinib on TGF-$\beta_1$-induced EMT [43]. Single compound treatment with TKI involves toxic effects at high concentrations, but in that study, EMT could be effectively inhibited when a cyclic peptide was added to a low concentration of TKI in combined treatment. Combination therapy using cilengitide also has been suggested as a way to improve the therapeutic efficacy of cancer treatment [30–33,44]. Clinical trials to evaluate the enhancement co-administration effect of cilengitide with conventional drugs are also ongoing or have been conducted [29,33,34]. In the meantime, many clinical studies have been conducted on the effects of co-administration of erlotinib with other drugs [22–25]. However, another co-administration strategy is also required because there is a limit to the co-administration of small molecule drugs and the possibility for conversion into resistant cells.

Although studies on cilengitide co-administration with various drugs are underway, the mechanism for EMT inhibition and the combination effects in NSCLC have not yet been examined. In a pair of studies on NSCLC cells, we have confirmed the inhibitory effect of cilengitide co-administration and the EGFR inhibitor gefitinib [36] or erlotinib (the current work) on EMT. Collectively, our findings show that the combination of cilengitide and EGFR inhibitors could represent a new chemotherapeutic option for modulating growth and invasive changes in EMT-associated NSCLC cell changes. Because EGFR inhibitors effectively inhibit downstream signaling even when used alone, we found little effect of cilengitide co-administration on EGFR signaling. The current study describes the co-administration effect of EGFR inhibitors and cilengitide only on EMT, and future studies should investigate the co-administration of cilengitide with other classes of NSCLC therapeutics. Among the various types of RGD-based cyclic peptides developed, cilengitide has been most investigated for its anticancer efficacy, but other peptides are understudied. In addition, with few studies evaluating the co-administration effect of small molecules and cyclic peptides in various diseases affected by EMT, the current findings offer a helpful basis for future research on inhibiting EMT-induced progression in other cancers.

We are currently synthesizing cyclic RGD peptide derivatives such as cilengitide and studying the effects of NSCLC cell growth inhibition and EMT inhibition. Through a recent study and this study, we verified the efficacy of TKIs such as gefitinib and erlotinib and cyclic RGD peptides in EMT. Based on these results, we plan to continuously study the effect of a new cyclic RGD peptide on NSCLC treatment and increase anticancer effect through co-administration. In addition, despite these findings, there is a need to diversify the approach to dealing with EMT according to the characteristics of lung epithelial cells. For example, in squamous carcinoma, Notch and Wnt signaling are shown to be very important, whereas in adenocarcinoma, RAS mutations occur frequently and have different biology. Therefore, we need to address these issues in more depth in future studies.

4. Materials and Methods

4.1. Materials

Erlotinib was purchased from Sigma–Aldrich (St. Louis, MO, USA), and cilengitide was synthesized by Kyeong-Yong Park (CHA Meditech Co., Ltd., Daejeon, Korea) (Figures S1–S3). Fetal bovine serum (FBS), RPMI-1640 medium, and antibiotics (100 U/mL penicillin and 100 $\mu$g/mL streptomycin) were purchased from Corning Inc. (Corning, NY, USA). Recombinant human TGF-$\beta_1$ was purchased from R&D Systems, Inc. (Minneapolis, MN, USA). Antibodies against E-cadherin (No. 3195), $\alpha$-smooth muscle actin ($\alpha$-SMA) (No. 19245), p-ERK1/2 (No. 4370), ERK1/2 (No. 4695), p-EGFR (No. 3777), EGFR (No. 4267), and p-Smad2/3 (No. 8828) were purchased from Cell Signaling Technology, Inc.
Antibodies against Smad2/3 (No. sc-133098), vimentin (No. sc-6260), N-cadherin (No. sc-59987), and β-catenin (No. sc-7199), horseradish peroxidase (HRP)-conjugated secondary antibodies (No. sc-516102 and No. sc-2357), HRP-conjugated actin (No. sc-1615), and HRP-conjugated β-actin (No. sc-47778) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).

4.2. Cell Culture and Cell Viability Assay

Bovine pulmonary epithelium CPAE (KCLB No. 10209), human lung fibroblast IMR90 (KCLB No. 10186), human NSCLC A549 (KCLB No. 10185), and H1299 (KCLB No. 91299) cell lines were obtained from Korean Cell Line Bank. All NSCLC and CPAE cells were maintained in RPMI-1640 medium (Corning, NY, USA), and IMR90 cells were maintained in minimum essential medium (Corning) containing 10% heat-inactivated FBS and 1% antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin). All cells were maintained at 37 °C in a humidified atmosphere of 5% CO2.

To assess cell viability, cells were seeded in 96-well plates for 24 h. After incubation, erlotinib or cilengitide were added for 24–72 h in culture medium containing 10% FBS. Cell viability was assessed using EZ-Cytox Enhanced Cell Viability Assay Kit (DogenBio, Seoul, Korea) according to the manufacturer’s instructions. The absorbance was measured by a Multiscan™ FC microplate photometer (Thermo Fisher Scientific, Waltham, MA, USA), and cell viability is presented as a percentage of control cells (untreated cells).

4.3. Western Blot Analysis

All cell lysates were prepared using Nuclear and Cytoplasmic Extraction Reagent (Thermo Fisher Scientific, Waltham, MA, USA). Quantified proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and incubated with specific primary antibodies and HRP-conjugated secondary antibodies. We used all primary or secondary antibodies diluted in TBST buffer containing 5% skim milk at a ratio of 1:1000. The band intensities were visualized using SuperSignal™ West Femto maximum sensitivity substrate (Thermo Fisher Scientific, Waltham, MA, USA) and measured using X-ray films and development solution (Fujifilm, Tokyo, Japan). The detected bands were quantified using ImageJ software (NIH, New York, NY, USA), and the relative ratios between each sample and the loading control are presented in this paper.

4.4. Invasion Assay

Serum-deprived A549 cells were treated with TGF-β1 (5 ng/mL) and erlotinib or cilengitide or their combination for 48 h. Cells were collected using trypsin-EDTA and resuspended in serum-free medium for counting. Culture medium (30 µL) containing 5% FBS was added to the bottom of a Boyden chamber. After placement of a gelatin-coated membrane filter, silicone gasket, and top chamber, the cell suspension (5 × 10^3 cells/50 µL) was added to the top chamber and incubated at 37 °C in 5% CO2 for 4 h. The membrane filter was collected, fixed, and stained using the Diff-Quick Staining Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions.

4.5. Quantitative Real-Time PCR (qRT-PCR) Analysis

Total RNA was isolated using the AccuPrep® RNA Extraction Kit (Bioneer Corp., Daejeon, Korea), and the cDNA was synthesized from 1 µg of total RNA using oligo (dT) primers (Bioneer Corp., Daejeon, Korea) and the RocketScript™ Reverse Transcriptase Kit (Bioneer Corp., Korea). qRT-PCR was performed using Prime Q-Mastermix (GeNet Bio, Daejeon, Korea) and the CFX96™ Real-Time System (Bio-Rad, Hercules, CA, USA). The cycling conditions were as follows: 95 °C for 3 min followed by 40 cycles at 95 °C for 15 s, 60 °C for 30 s, and 72 °C for 30 s. The primer sequences are shown in Table S1. All reactions were run in triplicate, and data were analyzed using the 2^{−ΔΔCT} method [41]. The internal standard was GAPDH. Significance was determined by the Student’s t-test with GAPDH-normalized 2^{−ΔΔCT} values [45].
4.6. Gelatin Zymography

A549 cells were incubated in a 6-well plate for 24 h. After serum starvation, cells were treated with TGF-β1 (5 ng/mL) and erlotinib or cilengitide, or their combination, for 48 h. The supernatants were collected, and centrifuged at 3000 × g for 10 min, and protein was concentrated using Amicon® Ultra Centrifugal Filters (Merck, Kenilworth, NJ, USA). After protein quantification using the BCA protein assay (Thermo Fisher Scientific, Waltham, MA, USA), proteins (40 µg) were loaded onto a gelatin-containing acrylamide gel and separated by electrophoresis. Protein separated gel was washed with 2.5% Tween-20 solution, developed overnight at 37 °C in Zymogram incubation buffer (50 mM Tris-HCl, pH 7.6; and 5 mM CaCl$_2$), stained with 0.25% Coomassie blue R250 solution, and destained with a solution of 50% methanol and 10% acetic acid until the part of membrane degraded by MMP-2 or MMP-9 became clear. The activity of matrix metalloproteinase (MMP)-2 and MMP-9 was measured according to a previously described experimental procedure [46].

4.7. Analysis of Combined Drug Effects

We analyzed the effects of the drug combination using the CalcuSyn software program (Biosoft, Cambridge, UK). To determine whether the result of treatment with the two compounds was additive or synergistic, we applied the combination index (CI) derived from the median effect principle of Chou and Talalay (1984) [47]. The CI was calculated using the formula published by Zhao et al. (2004) [48]. A CI of 1 indicates an additive effect between the two compounds, a CI > 1 indicates antagonism, and a CI <1 indicates synergism.

4.8. Statistical Analysis

Data are presented as the mean ± SD of at least three independent experiments. Significant differences were evaluated by one-way ANOVA with post-hoc Tukey HSD test. $p < 0.05$ was considered significant.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms23073423/s1.

Author Contributions: J.K. collected and analyzed the background research, J.J. created the figures, and J.K. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (Ministry of Science and NCT; 2020R1A2C1006416).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data are contained within the article or supplementary material.

Acknowledgments: We are grateful to the Kyeong-Yong Park who helped us with the experiment.

Conflicts of Interest: All authors declare that they have no conflict of interest. This work has not received any financial investment by CHA Meditech, Co., Ltd. The provider of cilengitide (CHA Meditech, Co., Ltd.) did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References
1. Siegel, R.; Ward, E.; Brawley, O.; Jemal, A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011, 61, 212–236. [CrossRef]
2. Duma, N.; Santana-Davila, R.; Molina, J.R. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin. Proc. 2019, 94, 1623–1640. [CrossRef] [PubMed]
3. Thiery, J.P.; Acloque, H.; Huang, R.Y.; Nieto, M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139, 871–890. [CrossRef]
4. Drabsch, Y.; ten Dijke, P. TGF-β signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 2012, 31, 553–568. [CrossRef] [PubMed]
5. Behrens, J.; Mareel, M.M.; Van Roy, F.M.; Birchmeier, W. Dissecting tumor cell invasion: Epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J. Cell Biol. 1989, 108, 2435–2447. [CrossRef] [PubMed]

6. Barcellos-Hoff, M.H.; Akhurst, R.J. Transforming growth factor-beta in breast cancer: Too much, too late. Breast Cancer Res. 2009, 11, 202. [CrossRef]

7. Buck, M.B.; Knabbe, C. TGF-beta signaling in breast cancer. Ann. N. Y. Acad. Sci. 2006, 1089, 119–126. [CrossRef]

8. Massagué, J.; Seoane, J.; Wotton, D. Smad transcription factors. Genes Dev. 2005, 19, 2783–2810. [CrossRef]

9. Heldin, C.H.; Miyazono, K.; ten Dijke, P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390, 465–471. [CrossRef]

10. Massagué, J. TGF-beta signal transduction. Annu. Rev. Biochem. 1998, 67, 753–791. [CrossRef]

11. Peinado, H.; Portillo, F.; Cano, A. Transcriptional regulation of cadherins during development and carcinogenesis. Int. J. Dev. Biol. 2004, 48, 365–375. [CrossRef]

12. Yang, J.; Mani, S.A.; Donaher, J.; Ramaswamy, L.; Itzykson, R.A.; Come, C.; Savagner, P.; Gitelman, I.; Richardson, A.; Weinberg, R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117, 927–939. [CrossRef] [PubMed]

13. Galliher, A.J.; Neil, J.R.; Schiemann, W.P. Role of transforming growth factor-beta in cancer progression. Future Oncol. 2006, 2, 743–763. [CrossRef] [PubMed]

14. Chen, X.F.; Zhang, H.J.; Wang, H.B.; Zhu, J.; Zhou, W.Y.; Zhang, H.; Zhao, M.C.; Su, J.M.; Gao, W.; Zhang, L.; et al. Transforming growth factor-β1 induces epithelial-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways. Mol. Biol. Rep. 2012, 39, 3549–3556. [CrossRef] [PubMed]

15. Medici, D.E.; Hay, D.; Olsen, B.R. Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. Mol. Biol. Cell 2008, 19, 4875–4887. [CrossRef] [PubMed]

16. Hsu, W.H.; Yang, J.C.; Mok, T.S.; Loong, H.H. Overview of current systemic management of EGFR-mutant NSCLC. Ann. Oncol. 2018, 29 (Suppl. 1), i3–i9. [CrossRef]

17. Molina, J.R.; Yang, P.; Cassivi, S.D.; Schild, S.E.; Adjei, A.A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 2008, 83, 584–594. [CrossRef] [PubMed]

18. Suda, K.; Tomizawa, K.; Fuji, M.; Murakami, H.; Osaka, H.; Maehara, Y.; Yatabe, Y.; Sekido, Y.; Mitsudomi, T. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J. Thorac. Oncol. 2011, 6, 1152–1161. [CrossRef]

19. Qu, Y.; Wu, X.; Yin, Y.; Yang, Y.; Ma, D.; Li, H. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models. J. Exp. Clin. Cancer Res. 2014, 33, 52. [CrossRef]

20. La Monica, S.; Madeddu, D.; Tiseo, M.; Vivo, V.; Galetti, M.; Cretella, D.; Bonelli, M.; Fumarola, C.; Cavazzoni, A.; Falco, A.; et al. Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation. J. Thorac. Oncol. 2016, 11, 1051–1063. [CrossRef]

21. Han, S.Y.; Zhao, W.; Sun, H.; Zhou, N.; Zhou, F.; An, G.; Li, P.P. Marsdenia tenacissima extract enhances gefitinib efficacy in non-small cell lung cancer xenografts. Phytomedicine 2015, 22, 560–567. [CrossRef] [PubMed]

22. Yang, Z.; Tam, K.Y. Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical and Clinical Results and Clinical Outcomes. Int. J. Biol. Sci. 2018, 14, 204–216. [CrossRef] [PubMed]

23. Yang, J.C.; Gadgeel, S.M.; Sequist, L.V.; Wu, C.L.; Papadimitrakopoulou, V.A.; Szotek, C.; Fiore, J.; Saraf, S.; Raftopoulos, H.; Patnaik, A. Pembrolizumab in Combination with Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC with Activating Mutation. J. Thorac. Oncol. 2019, 14, 1152–1161. [CrossRef]

24. Saito, H.; Fukuhara, T.; Furuya, N.; Watanabe, K.; Sugawara, S.; Iwasawa, J.; Tsunezuka, Y.; Yamaguchi, O.; Okada, M.; Yoshimori, K.; et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019, 20, 625–635. [CrossRef] [PubMed]

25. Yue, D.; Xu, S.; Wang, Q.; Li, X.; Shen, Y.; Zhao, H.; Chen, C.; Mao, W.; Liu, W.; Liu, J.; et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): A randomised, open-label, phase 2 trial. Lancet Respir. Med. 2018, 6, 863–873. [CrossRef]

26. Mas-Moruno, C.; Rechenmacher, F.; Kessler, H. Cilengitide: The first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med. Chem. 2010, 10, 753–768. [CrossRef] [PubMed]

27. Plow, E.F.; Haas, T.A.; Zhang, L.; Loftus, J.; Smith, J.W. Ligand binding to integrins. J. Biol. Chem. 2000, 275, 21785–21788. [CrossRef] [PubMed]

28. Heckman, D.; Kessler, H. Design and chemical synthesis of integrin ligands. Methods Enzymol. 2007, 426, 463–503. [CrossRef] [PubMed]

29. Cox, D.; Brennan, M.; Moran, N. Integrins as therapeutic targets: Lessons and opportunities. Nat. Rev. Drug Discov. 2010, 9, 804–820. [CrossRef] [PubMed]
31. Heiduschka, G.; Lill, C.; Schneider, S.; Seemann, R.; Kornek, G.; Schmid, R.; Kotowski, U.; Thurnher, D. The effect of cilengitide in combination with irradiation and chemotherapy in head and neck squamous cell carcinoma cell lines. Strahlenther. Onkol. 2014, 190, 472–479. [CrossRef]

32. Lautenschlaeger, T.; Perry, J.; Peereboom, D.; Li, B.; Ibrahim, A.; Huebner, A.; Meng, W.; White, J.; Chakravarti, A. In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines. Radiat. Oncol. 2013, 8, 246. [CrossRef]

33. Zeng, X.; Wan, X.; Xu, J.; Wang, H.; Chen, H.; Zeng, Q.; Zhang, W.; Zhao, B. Therapeutic options for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer: A Bayesian network secondary analysis. Aging 2020, 12, 7129–7162. [CrossRef]

34. Haddad, T.; Qin, R.; Lupu, R.; Satele, D.; Eadens, M.; Goetz, M.P.; Erlichman, C.; Molina, J. A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2017, 79, 1221–1227. [CrossRef] [PubMed]

35. Massabeau, C.; Khalifa, J.; Filleron, T.; Modesto, A.; Bigay-Gamé, L.; Plat, G.; Dierrichx, L.; Aziza, R.; Rouquetter, L.; Gomez-Roca, C.; et al. Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients with Stage III Non-Small-cell Lung Cancer: A Phase I Study. Clin. Lung Cancer 2018, 19, e277–e285. [CrossRef]

36. Jeong, J.; Kim, J. Cyclic RGD Pentapeptide Cilengitide Enhances Efficacy of Gefitinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Invasion in Human Non-Small Cell Lung Cancer Cells. Front. Pharmacol. 2021, 12, 639095. [CrossRef] [PubMed]

37. Najafi, M.; Farhood, B.; Mortezaee, K. Extracellular matrix (ECM) stiffness and degradation as cancer drivers. J. Cell. Biochem. 2019, 120, 2782–2790. [CrossRef] [PubMed]

38. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119, 1420–1428, Erratum in: J. Clin. Investig. 2010, 120, 1786. [CrossRef]

39. Jakobsen, K.R.; Demuth, C.; Sorensen, B.S.; Nielsen, A.L. The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Transl. Lung Cancer Res. 2016, 5, 172–182. [CrossRef]

40. On, Y.S.; Gao, L.; Kalesh, K.A.; Yu, Z.; Wang, J.; Liu, C.; Li, Y.; Sun, H.; Lee, S.S. Recent Advances in Synthesis and Identification of Cyclic Peptides for Bioapplications. Curr. Top Med. Chem. 2017, 17, 2302–2318. [CrossRef]

41. Kulhari, H.; Pooja, D.; Kota, R.; Reddy, T.S.; Tabor, R.F.; Shukla, R.; Adams, D.J.; Sistla, R.; Bansal, V. Cyclic RGDfK Peptide Functionalized Polymeric Nanocarriers for Targeting Gemcitabine to Ovarian Cancer Cells. Mol. Pharm. 2016, 13, 1491–1500. [CrossRef] [PubMed]

42. Chen, K.; Chen, X. Integrin targeted delivery of chemotherapeutics. Theranostics 2011, 1, 189–200. [CrossRef] [PubMed]

43. Park, K.Y.; Kim, J. Cyclic pentapeptide cRGDfK enhances the inhibitory effect of sunitinib on TGF-β1-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells. PloS ONE 2020, 15, e0232917. [CrossRef]

44. Wichmann, G.; Cedra, S.; Schlegel, D.; Kolb, M.; Wiegand, S.; Boehm, A.; Hofer, M.; Dietz, A. Cilengitide and Cetuximab Reduce Cytokine Production and Colony Formation of Head and Neck Squamous Cell Carcinoma Cells. Ex Vivo Anticancer Res. 2017, 37, 521–527. [CrossRef]

45. Livak, K.J.; Schnittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta Ct) Method. Methods 2001, 25, 402–408. [CrossRef]

46. Kim, J.; Moon, S.H.; Kim, B.T.; Chae, C.H.; Lee, J.Y.; Kim, S.H. A novel aminothiazole KY-0509 with potential to inhibit Traf2- and Nck-interacting kinase (TNIK) attenuates TGF-β1-mediated epithelial-to-mesenchymal transition in human lung adenocarcinoma A549 cells. PloS ONE 2014, 9, e110180. [CrossRef]

47. Chou, T.C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Regul. 1984, 22, 27–55. [CrossRef]

48. Zhao, L.; Wientjes, M.G.; Au, J.L. Evaluation of combination chemotherapy: Integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin. Cancer Res. 2004, 10, 7994–8004. [CrossRef]